GlassScriptPhysician profile
Donna B Chan
NPI 1194155994
$1,345.74
in general payments reported to CMS, 2019-2025
23 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $30.37 · 2023: $448 · 2024: $221 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $259.66 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $208.83 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $142.00 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Neurocrine Biosciences, INC. | $125.00 | 2021 | |
| Cranial Technologies, INC | $71.58 | 2021-2024 | Doc Band |
| Sanofi Pasteur INC. | $70.27 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.36 | 2023-2025 | Jardiance |
| Amgen INC. | $52.57 | 2021-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $46.48 | 2022-2025 | Bexsero, Penmenvy |
| Bayer Healthcare Pharmaceuticals INC. | $40.16 | 2023-2025 | |
| Novo Nordisk INC | $36.87 | 2023 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $31.31 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $30.58 | 2025 | Zoryve |
| Sage Therapeutics, LLC | $26.48 | 2025 | Zurzuvae |
| Ultragenyx Pharmaceutical INC. | $22.22 | 2024 | Crysvita |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.99 | 2025 | Freestyle Libre 3 |
| Agile Therapeutics, INC. | $18.88 | 2024 | Twirla |
| Pfizer INC. | $16.74 | 2025 | |
| Sobi, INC | $15.43 | 2023 | |
| Verrica Pharmaceuticals INC. | $14.92 | 2025 | Ycanth |
| Neurelis, INC. | $14.24 | 2023 | Valtoco |
| Organon LLC | $12.95 | 2025 | Nexplanon |
| Phathom Pharmaceuticals, INC. | $12.22 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.